3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 3
3
Phase NA
1
Status
Completed
2
Unknown
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
4
Plasma cell
3
Other hematologic neoplasm
3
Thoracic
2
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Multiple Myeloma
3
Smoldering Multiple Myeloma
1
Neoplasms, Plasma Cell
1
Interventions
Dexamethasone
178
Bortezomib
100
Lenalidomide
90
daratumumab
47
Melphalan
46
Thalidomide
44
pomalidomide
43
Cyclophosphamide
38
Calcium Dobesilate
30
carfilzomib
29
Prednisone
19
Doxorubicin
16
elotuzumab
14
Filgrastim
14
isatuximab
12
ixazomib
11
Granulocyte Colony-Stimulating Factor
11
Vincristine
10
Peripheral Blood Stem Cell Transplantation
10
dexamethasone acetate
9
belantamab mafodotin
9
Zoledronic Acid
8
selinexor
7
Epoetin Alfa
7
fludarabine
6
Etoposide
6
dexamethasone 21-phosphate
5
auricularum
5
Mycophenolic Acid
5
Cisplatin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Maintenance
×
Plasma cell
×
Clear all
NCT01554852
2018-06-11
Myeloma XI
University of Leeds
Phase 3
Unknown
4,420 enrolled
NCT00480363
2013-07-31
QUIREDEX
PETHEMA Foundation
Phase 3
Completed
120 enrolled
NCT00560053
2008-11-27
Pethema Multiple Myeloma 2000
PETHEMA Foundation
Phase 3
Completed
500 enrolled